Rucaparib is a potent and selective inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, which is used in the treatment of ovarian cancer. Rucaparib impurities are minor components that can be present in the drug substance or drug product. These impurities can affect the quality, safety, and efficacy of the drug product. It is essential to control and monitor the levels of impurities during the manufacturing process and throughout the product's shelf life. The identification and quantification of Rucaparib impurities are critical to ensure the quality of the drug product.
